- Home
- KNSA vs AB Comparison
KNSA vs AB Comparison
Compare KNSA & AB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSA | AB |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2018 | 1994 |
Fundamental Metrics
Financial Performance| Metric | KNSA | AB |
|---|---|---|
| Price | $46.09 | $37.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 5 |
| Target Price | ★ $55.29 | $42.00 |
| AVG Volume (30 Days) | ★ 672.2K | 341.6K |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 9.11% |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $38.01 | N/A |
| Revenue Next Year | $17.42 | $7.40 |
| P/E Ratio | $61.35 | ★ $13.85 |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $18.26 | $32.28 |
| 52 Week High | $49.12 | $44.11 |
Technical Indicators
Market Signals| Indicator | KNSA | AB |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 41.44 |
| Support Level | $39.96 | N/A |
| Resistance Level | $48.14 | $39.77 |
| Average True Range (ATR) | 1.79 | 0.93 |
| MACD | -0.15 | -0.08 |
| Stochastic Oscillator | 58.86 | 21.60 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (41%), and private (18%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of January 2026, the company had $875.0 billion in managed assets, composed primarily of fixed-income (36% of AUM) and equity (41%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.